成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Journal of Dermatological Treatment >>article
Journal of Dermatological Treatment

Journal of Dermatological Treatment

IF: 2.89
Download PDF

Baricitinib for the treatment of atopic dermatitis.

Published:1 August 2022 DOI: 10.1080/09546634.2021.1967268 PMID: 34379541
Amelia Melo, Jose Manuel Carrascosa, Tiago Torres

Abstract

Atopic dermatitis is a common, chronic and recurrent inflammatory skin disease, which often appears in childhood but can last into adulthood. It negatively impacts patients, their families and society in general. There is a therapeutic unmet need, with patients requiring new drugs that are safe and effective. The increasing knowledge of the pathophysiology of AD and the role of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway in the development and maintenance of AD, has led to the development of agents blocking this intracellular signaling pathway, the JAK inhibitors. Baricitinib shows high selectivity for JAK1 and JAK2, making it appealing for the treatment of this condition. Phase II and phase III trials evaluated the efficacy and safety of baricitinib in the treatment of AD, and the results have been encouraging, showing a good efficacy and a favorable safety and tolerability profile. At the end of 2020, EMA approved baricitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, increasing the therapeutic option for this debilitating disease.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Baricitinib 1187594-09-7 C16H17N7O2S 492 suppliers $37.00-$1802.00
TransAM STAT Family 6 suppliers Inquiry
Jak Isoform Sampler Kit 5 suppliers Inquiry

Similar articles

IF:13

Baricitinib for the Treatment of Alopecia Areata.

Drugs Egídio Freitas, Emma Guttman-Yassky,etc Published: 1 June 2023
IF:4.5

Topical delivery of tofacitinib citrate loaded novel nanoemulgel for the management of 2,4-Dichlorodinitrobenzene induced atopic dermatitis in mice model

Journal of Drug Delivery Science and Technology Srividya Atmakuri , Shweta Nene ,etc Published: 1 February 2023